American Century Companies Inc. Purchases 66,517 Shares of Masimo Corporation $MASI

American Century Companies Inc. lifted its position in Masimo Corporation (NASDAQ:MASI) by 525.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,176 shares of the medical equipment provider’s stock after acquiring an additional 66,517 shares during the quarter. American Century Companies Inc. owned 0.15% of Masimo worth $13,191,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its holdings in shares of Masimo by 8.6% in the first quarter. Dimensional Fund Advisors LP now owns 703,378 shares of the medical equipment provider’s stock valued at $117,172,000 after acquiring an additional 55,658 shares in the last quarter. Vestmark Advisory Solutions Inc. raised its holdings in shares of Masimo by 6.1% in the first quarter. Vestmark Advisory Solutions Inc. now owns 3,274 shares of the medical equipment provider’s stock valued at $545,000 after acquiring an additional 189 shares in the last quarter. Mitsubishi UFJ Asset Management UK Ltd. bought a new stake in shares of Masimo in the first quarter valued at about $1,333,000. Russell Investments Group Ltd. raised its holdings in shares of Masimo by 76.4% in the first quarter. Russell Investments Group Ltd. now owns 34,747 shares of the medical equipment provider’s stock valued at $5,789,000 after acquiring an additional 15,044 shares in the last quarter. Finally, Informed Momentum Co LLC bought a new stake in shares of Masimo in the first quarter valued at about $3,824,000. 85.96% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director William R. Jellison acquired 3,000 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were purchased at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the acquisition, the director directly owned 4,790 shares in the company, valued at $699,244.20. The trade was a 167.60% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.90% of the stock is currently owned by company insiders.

Masimo Stock Performance

MASI opened at $145.15 on Tuesday. Masimo Corporation has a 52-week low of $107.98 and a 52-week high of $194.88. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. The company has a market cap of $7.89 billion, a P/E ratio of -17.04 and a beta of 1.21. The firm’s 50-day moving average price is $158.85 and its 200-day moving average price is $162.54.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.11. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The firm had revenue of $370.90 million for the quarter, compared to the consensus estimate of $368.65 million. During the same quarter in the prior year, the company posted $0.86 earnings per share. The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. As a group, equities analysts anticipate that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Raymond James Financial decreased their price objective on Masimo from $204.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. Piper Sandler lifted their target price on Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered Masimo from a “buy” rating to a “hold” rating in a research note on Friday, May 30th. BTIG Research reiterated a “buy” rating on shares of Masimo in a research note on Thursday, August 14th. Finally, Wells Fargo & Company cut their target price on Masimo from $205.00 to $190.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 7th. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Masimo currently has a consensus rating of “Moderate Buy” and an average price target of $193.60.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.